北京商报讯（记者王寅浩实习记者宋雨盈）8月28日，神州细胞发布公告称，2025年上半年实现营业收 入9.72亿元，同比下降25.5%；归属于上市公司股东的净利润亏损3377.11万元，同比下降126.87%；归 属于上市公司股东的扣除非经常性损益的净利润亏损3610.82万元，同比下降110.61%。 （文章来源：北京商报） ...

Group 1 - The core viewpoint of the article highlights that Shenzhou Cell reported a significant decline in revenue and a shift from profit to loss in the first half of 2025, primarily due to price reductions from regional alliances and healthcare cost controls [1][2] - In the first half of 2025, Shenzhou Cell's revenue was 972 million yuan, a year-on-year decrease of 25.50%, and the net profit attributable to shareholders was -33.77 million yuan, indicating a loss compared to previous profits [1] - The decline in revenue is attributed to decreased sales of core products, while the profit drop is linked to high R&D and sales expenses, despite efforts to reduce costs through new product launches and supply chain optimization [1] Group 2 - Shenzhou Cell is actively advancing multiple innovative drug developments, including clinical research on products like SCTV04C and SCT520FF, and has initiated a refinancing project to support R&D and optimize its capital structure [1] - The global biopharmaceutical industry continued to recover in the first half of 2025, with an expanding market size and active technological innovation, supported by favorable policies in China that enhance innovation capabilities [2] - As of August 28, 2025, Shenzhou Cell's stock price was 64.28 yuan per share, down 1.85%, with a total market capitalization of 28.626 billion yuan, reflecting a 9.97% decline over the past seven trading days [2]

北京神州细胞生物技术集团股份公司（以下简称"公司"或"神州细胞"） 为切实践行"以投资者为本"的上市公司发展理念，维护公司全体股东特别是广 大中小投资者利益，基于对公司未来发展前景的信心和真抓实干提升公司投资价 值的责任感，于 2025 年 4 月 26 日发布了公司《2024 年度"提质增效重回报" 行动评估报告暨 2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"）， 为公司 2025 年度"提质增效重回报"行动制定了行动纲领和具体的工作计划。 公司根据行动方案内容，积极开展和落实各项工作，现将相关措施的实施效果评 估情况报告如下： 一、"全线产品协同增效，推动公司持续高质量发展"的实施情况 北京神州细胞生物技术集团股份公司 2025 年度"提质增效重回报"行动方案的半年度评估报告 2025 年上半年，公司实现营业收入 9.72 亿元，受地区及地区联盟集采降价、 医保控费等因素影响，重组凝血八因子整体市场规模收缩，公司核心产品安佳因 ®的销售表现相应承压。在此背景下，公司积极应对，借助精准的市场策略，确 保重点省份的集采中标和价格调整幅度优于行业平均。同时，公司持续深化下沉 市场的渠道拓展， ...

公司代码：688520 公司简称：神州细胞 北京神州细胞生物技术集团股份公司 2025 年半年度报告 北京神州细胞生物技术集团股份公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在报告中详细描 述可能存在的相关风险，敬请查阅本报告第三节"管理层讨论与分析"之"四、风险因素"部分 内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人谢良志、主管会计工作负责人谢良志及会计机构负责人（会计主管人员）马洁 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司规划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬请 投资者注意相关风险。 九、 是否存在被控股股 ...

神州细胞公告，2025年上半年营业收入9.72亿元，同比下降25.50%。净利润亏损3377.11万元，上年同 期净利润1.26亿元。 ...

Group 1 - The recent court ruling revealed a fraudulent insurance scheme involving Shenzhou Cell's subsidiary, where sales staff induced patients to falsely claim medical conditions for profit [1] - The core product involved in the fraud is "Anjain," a recombinant coagulation factor VIII product, which has become a significant revenue driver for Shenzhou Cell since its launch in 2021 [1] - Anjain's sales skyrocketed from 134 million to 1.89 billion, accounting for over 75% of the company's total revenue of 2.5 billion in 2024, while sales expenses surged nearly 20 times from 24.77 million in 2021 to 456 million in 2024 [1] Group 2 - In Q1 2025, Shenzhou Cell's revenue declined by 15.15% year-on-year, and net profit fell by 14.06%, attributed to price reductions and cost controls in the healthcare sector [2] - The price of Anjain has dropped to around 2000 yuan due to competitive bidding, nearing the price of human-derived factor VIII, highlighting the intense price war in the market [2] - The misalignment between healthcare policies and clinical needs poses a challenge for Shenzhou Cell, as the current reimbursement policy restricts coverage to cases of bleeding, while preventive treatment is crucial for patients [2]

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Overview - The monoclonal antibody (mAb) market in China is still in its early stages, with many overseas mAbs not yet approved domestically. The high cost of these drugs limits accessibility for many patients with lower payment capabilities. However, the market penetration of mAbs is gradually increasing due to their significant advantages over traditional drugs, updates to the national medical insurance catalog, and rising national income levels. The market size of China's mAb industry is projected to reach 131.5 billion yuan in 2024, representing a year-on-year growth of 30.85% [1][5]. Industry Chain - The upstream of the mAb industry includes suppliers of raw materials such as cell culture media, enzymes, antibodies, reagents, consumables, and packaging materials, as well as core equipment suppliers like bioreactors and purification devices. The midstream consists of mAb research and production companies, while the downstream includes hospitals, DTP pharmacies, retail pharmacies, and online channels. Hospitals are the most critical distribution channel for mAbs in China, especially for drugs listed in the medical insurance catalog [3][5]. Development Background - The application of mAbs in cancer treatment is widespread, with the number of new cancer cases in China projected to reach 5.064 million in 2024, a year-on-year increase of 2.61%. This growing cancer population drives the demand for mAbs. Additionally, mAbs have shown efficacy in treating other diseases, such as asthma and inflammatory bowel diseases, providing new development opportunities for the mAb industry [4][5]. Current Status - Since the launch of the first therapeutic mAb in 1986, the mAb market has rapidly developed, with significant products like trastuzumab and adalimumab emerging. By 2024, the global mAb market size is expected to reach 273.3 billion USD, with a year-on-year growth of 9.15% [4][5]. Competitive Landscape - In the global pharmaceutical market, mAbs are becoming a cornerstone of biopharmaceuticals, with 8 mAbs appearing in the top 20 global drug sales rankings in 2024. The success of mAbs in treating tumors and immune diseases is notable, and advancements in biopharmaceutical technology may expand their role in treating infectious diseases [5][6]. Domestic Market Dynamics - In 2024, only 7 mAbs are among the top 30 chemical and biological drugs sold in Chinese hospitals, indicating significant room for growth in the domestic mAb market. The market is expected to expand further as domestic companies gain market share [7][8]. Company Analysis - Domestic companies like BeiGene, Innovent Biologics, Junshi Biosciences, and others are increasingly capturing market share previously dominated by multinational corporations. For instance, BeiGene's Tislelizumab leads in the PD-1 mAb market in China, while Innovent's Sintilimab and Junshi's Toripalimab also hold significant positions [8][9]. Future Trends - The quality and efficacy of domestic mAbs are expected to improve with ongoing advancements in research and production technologies. This may lead to a further increase in market share, breaking the monopoly of multinational companies. Additionally, the application of mAbs is anticipated to expand beyond cancer and autoimmune diseases to include infectious and transmissible diseases [11].

〔2025〕104 号），上交所依据相关规定对公司报送的科创板上市公司发行 证券的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法 定形式，决定予以受理并依法进行审核。 公司本次向特定对象发行 A 股股票事项尚需通过上交所审核，并获得中国 证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实 施，最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存 在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投 资者注意投资风险。 特此公告。 北京神州细胞生物技术集团股份公司董事会 证券代码：688520 证券简称：神州细胞 公告编号：2025-038 北京神州细胞生物技术集团股份公司 关于 2025 年度向特定对象发行 A 股股票申请获得 上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）于 2025 年 8 月 胞生物技术集团股份公司科创板上市公司发行证券申请的通知》（上证科审（再 融资） ...

Core Viewpoint - The company, Sinocelltech Group Limited, is preparing for a specific issuance of A-shares in 2025, aiming to raise up to 900 million RMB to enhance its liquidity and support its ongoing research and development in the biopharmaceutical sector [1][18][24]. Company Overview - Sinocelltech Group Limited was established on April 23, 2007, and became a joint-stock company on March 19, 2019, with a registered capital of 445.34 million RMB [2][3]. - The company focuses on the research and development of innovative biopharmaceuticals, particularly in the treatment of malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders [3][4]. Business Operations - The company has developed a high-efficiency, high-throughput technology platform for biopharmaceutical research and production, with a diverse pipeline including monoclonal antibodies, recombinant proteins, and innovative vaccines [3][4][5]. - As of the date of the report, the company has one recombinant protein drug and four antibody drugs approved for market, with three vaccine products included for emergency use, and several others in clinical research [3][7]. Financial Performance - The company reported revenues of 102.32 million RMB, 188.73 million RMB, and 251.27 million RMB for the years 2022, 2023, and 2024 respectively, indicating a significant growth trajectory [7][8]. - The total assets as of December 31, 2024, were approximately 344.96 million RMB, with total liabilities of about 325.11 million RMB, resulting in shareholders' equity of 19.85 million RMB [8][9]. Issuance Details - The upcoming issuance will involve the sale of up to 25 million shares at a price of 36.00 RMB per share, which is not less than 80% of the average trading price over the 20 trading days prior to the pricing date [17][18]. - The funds raised will be used entirely to supplement the company's working capital [18][24]. Regulatory Compliance - The company has undergone due diligence and has been deemed compliant with relevant laws and regulations governing securities issuance and listing [22][24]. - The issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [24].